Expression of IRAK1 Gene rs1059703-related Single- Nucleotide Polymorphisms in Egyptian Patient With Rheumatoid Arthritis

• Sponsor: Sohag University (Other)
• Overall Status: Recruiting
• CT.gov ID: NCT05588817
• Collaborator: (none)
• Enrollment: 90
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 11
• Patients Per Site Per Month: 8.2

Study Details

Study Description

Brief Summary

Rheumatoid arthritis (RA) is known as a long-lasting inflammatory autoimmune disease affecting the diarthrodial joints, which is diagnosed by inflammation and hyperplasia in synovium, generation of RF and anti-citrullinated protein antibody (ACPA), deformity of cartilage and bone, systemic injuries involving cardiovascular, pulmonary, psychological, and skeletal disorders (McInnes and Schett., 2011).

Condition or Disease	Intervention/Treatment	Phase
Rheumatoid Arthritis (RA)	Genetic: PCR polymorphism	N/A

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 90 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: Expression of IRAK1 Gene rs1059703-related Single- Nucleotide Polymorphisms in Egyptian Patient With Rheumatoid Arthritis
• Anticipated Study Start Date: Dec 30, 2022
• Anticipated Primary Completion Date: Dec 1, 2023
• Anticipated Study Completion Date: Dec 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Group 1 Normal control	Genetic: PCR polymorphism; PCR polymorphism in Rhomatoid arthritis patients in Egypt
Active Comparator: Group 2 Diagnosed Rhomatoid arthritis patients	Genetic: PCR polymorphism; PCR polymorphism in Rhomatoid arthritis patients in Egypt

Outcome Measures

Primary Outcome Measures

1. rs1059703 PCR polymorphism in rhomatoid arthritis patients [1 year]

   PCR polymorphism

Eligibility Criteria

Criteria

• Ages Eligible for Study: 17 Years to 85 Years
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• approval to sign an informed written consent, patient diagnosed rheumatoid arthritis, patient age range 17-85 year and both sexes are included.

Exclusion Criteria:

• Refusal to sign an informed written consent and patient with other autoimmune disease.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Sohag university hospital	Sohag		Egypt

Sponsors and Collaborators

• Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Alaa atef Abdelsalam, Assistant lecturer, Sohag University
• ClinicalTrials.gov Identifier: NCT05588817
• Other Study ID Numbers: Soh_Med_22_10_15
• First Posted: Oct 20, 2022
• Last Update Posted: Oct 20, 2022
• Last Verified: Oct 1, 2022

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Arthritis; Arthritis, Rheumatoid

Study Results

No Results Posted as of Oct 20, 2022